Navigation Links
Appeal Court's Direction on Claim Construction Is Strategically Important for Butamax's Case Against Gevo Scheduled for April 2013
Date:11/19/2012

WILMINGTON, Del., Nov. 19, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, commented on the decision by the Federal Circuit.  While the Federal Circuit affirmed the District Court's preliminary injunction decision, Butamax is pleased with the Federal Circuit's direction on claim construction.  The District Court's narrow interpretation of Butamax's patent was not endorsed and, in the words of the Federal Circuit:

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"…this court's affirmance should not be read to endorse the trial court's very questionable construction of the claim term "acetohydroxy acid isomeroreductase" – that is "as an enzyme that is solely NADPH dependent.  The trial court should reconsider its construction when it holds a Markman hearing."

Gevo had argued that it did not infringe Butamax's patent because of this narrowed scope of the KARI enzyme.  Butamax is confident that, with a revised claim construction, it will succeed in its infringement arguments against Gevo.  The Federal Circuit also commented that Butamax did not demonstrate that Gevo's arguments on validity lacked substantial merit as required for the grant of a preliminary injunction. Butamax will address these issues at the April 2013 trial, which will also cover the full scope of the '188 and '889 patents.

About Butamax
Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit

SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
2. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
3. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
4. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
5. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. The Energy Scientific World Acclaims the Global Energy Prize 2012 Laureates
9. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
10. MetaStat, Inc. Announces Allowance of Patent Claims
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
(Date:2/26/2015)... Protiviti ( www.protiviti.com ), a global consulting ... Governance Portal , designed to increase the efficiency with ... across multiple business units and projects. The Governance Portal ... align their controls with the COSO ( Committee of ... response to client feedback, Protiviti has also included a ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... 23 Summary: At Genmab A/S,Annual General Meeting held ... was approved, discharge was given to the Board of ... forward. Two members of the,Board of Directors were re-elected ... proposals from the Board of,Directors to change the Articles ...
... Calif., April 23 STAAR Surgical,Company (Nasdaq: ... of,minimally invasive ophthalmic products, today announced very strong,participation ... on the Company,s,Visian ICL(TM) (Implantable Collamer Lens). The ... "How My Website Compels Patients to Call,Me," is ...
... April 23 Two,leading companies in the ... a new commercial alliance. IOTA Pharmaceuticals Ltd, ... in Uppsala, Sweden, will join forces,to deploy ... The IOTA-Beactica platform couples comprehensive, site-directed ...
Cached Biology Technology:Passing of Genmab A/S' Annual General Meeting 2Passing of Genmab A/S' Annual General Meeting 3Passing of Genmab A/S' Annual General Meeting 4More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 2More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 3New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden) 2
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Ore. For several years, the pharmaceutical industry has ... receptor in the brain, the NMDA receptor. This receptor ... brain and is involved in learning and memory. NMDA ... psychiatric conditions such as Alzheimer,s disease, Parkinson,s disease, schizophrenia ...
... J. Carver Charitable Trust has awarded a $2 million ... University of Illinois at Urbana-Champaign. Under the leadership of ... Christopher Rao, the grant will be disbursed over two ... new research theme devoted to the new scientific subdiscipline ...
... Journal of Animal Science suggests producers may ... grains with solubles (DDGS). Some producers believe that feeding ... DDGS. Firmer fat means longer-lasting pork. But researchers ... fats in DDGS diets makes no difference in fat ...
Cached Biology News:OHSU scientists advance understanding of brain receptor; may help fight neurological disorders 2Roy J. Carver Charitable Trust funds new research focus at Institute for Genomic Biology 2Saturated fats do not yield better bacon 2
...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
... with carbonyl diimidazole chemistry that covalently binds ... array contains the same binding chemistry as ... updated hydrophobic barrier coating. These arrays are ... spots spatially compatible with one column of ...
Biology Products: